European CNS & Neuroscience Therapeutics 2026: Alzheimer, Parkinson, CNS, Pain

H. Lundbeck A/S (Copenhagen) is the directory’s largest dedicated CNS pharma, focused on brain research and commercial-stage psychiatric + neurological therapeutics. Lundbeck runs commercial products across depression (Trintellix / Brintellix vortioxetine partnered with Takeda; Cipralex / Lexapro escitalopram), schizophrenia (Rexulti brexpiprazole partnered with Otsuka; Abilify Maintena and Abilify Asimtufii long-acting aripiprazole), Alzheimer-agitation (Rexulti Alzheimer indication approved by FDA 2023), and migraine (Vyepti eptinezumab launched 2020). For sponsors evaluating European CNS commercial partnership, licensing, or pipeline collaboration, Lundbeck is the largest dedicated CNS pharma the directory covers.

BioArctic (Stockholm) holds the directory’s most-developed European Alzheimer’s programme through its lecanemab partnership with Eisai (commercialised as Leqembi). Leqembi was approved by the FDA in 2023 (full approval) and by EMA in 2025 for early Alzheimer’s with confirmed amyloid pathology. BioArctic also runs a wider neurodegenerative pipeline including alpha-synuclein-targeting Parkinson’s programmes (exidavnemab partnered with AbbVie under the BAN0805 collaboration umbrella) and additional Alzheimer-related candidates beyond lecanemab. For sponsors evaluating the European amyloid-targeting + tau-targeting + alpha-synuclein-targeting neurodegenerative landscape, BioArctic is the directory’s commercial-stage Swedish operator with an active partnership backbone.

Switzerland hosts four directory-listed CNS + neurodegenerative operators. Idorsia (Allschwil, near Basel) runs commercial-stage sleep therapeutics (Quviviq daridorexant approved by FDA + EMA in 2022) plus a CNS pipeline. Noema Pharma (Basel) develops CNS + rare neurology + orphan-indication therapeutics derived from ex-Roche assets (mGluR5 antagonist programmes including basimglurant and additional ex-Roche-derived candidates). Gain Therapeutics (Lugano) develops allosteric small-molecule therapeutics for rare neurodegenerative diseases (GBA1-targeted programmes for Parkinson’s and Gaucher disease). Innomedica (Bern) develops liposomal nanomedicine including Talineuren for CNS indications. Together these four operators cover the Swiss CNS clinical-stage landscape; Memo Therapeutics (Schlieren) adjacent in antibody discovery for neurology-relevant targets.

Beyond the big-pharma CNS anchors, the directory surfaces specialised clinical-stage operators. Hoba Therapeutics (Copenhagen) develops non-opioid chronic pain + sensorineural hearing loss + peripheral nervous system targets — a distinct CNS-adjacent specialty. Herantis Pharma (Espoo, Finland) runs neuroinflammation + CNS biologics + translational drug development with a focus on neurodegeneration. Pikralida (Poznań) operates Polish CNS medicinal chemistry + drug discovery for civilizational diseases of the elderly. Adamant Health (Kuopio) develops wearable medical devices + surface EMG analytics for Parkinson’s symptom quantification — adjacent to CNS therapeutics as a digital biomarker platform.

Poland holds two directory operators with significant CNS portfolios. Celon Pharma (Łomianki) runs integrated R&D and manufacturing across oncology and neurology. Adamed Pharma (Pienkow) runs an integrated pharmaceutical R&D + manufacturing business with CNS, oncology, cardiology, and respiratory portfolios. Both are domestic Polish pharma with CNS programmes contributing to the wider Polish biotech landscape (covered in the Polish Biotech Landscape 2026 brief). Pikralida (Poznań) adds the Polish CNS-medicinal-chemistry discovery layer.

European CNS therapeutic programmes need matching diagnostic + biomarker capacity. GLX Analytix (Copenhagen) develops glycomics-based biomarkers for neurodegenerative + autoimmune disease monitoring. Hummingbird Diagnostics (Heidelberg) operates miRNA-based liquid biopsy with neurology indications alongside oncology. CeGaT (Tübingen) provides clinical NGS + whole-exome / whole-genome sequencing for genetic neurology diagnoses. For preclinical neuroscience CRO services, Charles River Laboratories Finland (Kuopio) provides in-vivo pharmacology + imaging + biomarker analysis + translational research at its Kuopio site. The European Drug Discovery Services 2026 and European Diagnostics Landscape 2026 briefs cover the wider CRO + IVD picture.

TolerogenixX (Heidelberg) develops tolerogenic dendritic cell therapy for autoimmune disease + transplant medicine — relevant to multiple sclerosis and other autoimmune CNS conditions. PolTREG (Gdansk) develops T-regulatory cell therapy for Type 1 diabetes and multiple sclerosis. Both sit at the intersection of cell therapy and CNS / autoimmune treatment. The Cell & Gene Therapy Europe 2026 brief covers the broader cell-therapy modality.

Match the decision to the modality + indication. Commercial CNS partnership / licensing: Lundbeck (Copenhagen, depression, schizophrenia, Alzheimer-agitation, Huntington’s, migraine). Alzheimer’s antibody partnership: BioArctic (Stockholm, lecanemab partner of Eisai). Sleep + commercial CNS: Idorsia (Allschwil, Quviviq). CNS + rare neurology orphan partnership: Noema Pharma (Basel, ex-Roche assets). Allosteric small-molecule neurodegenerative: Gain Therapeutics (Lugano). Non-opioid chronic pain: Hoba Therapeutics (Copenhagen). Neuroinflammation biologics: Herantis Pharma (Espoo). CNS medicinal chemistry CRO + discovery: Pikralida (Poznań) or Charles River Laboratories Finland (Kuopio). Multiple sclerosis cell therapy: PolTREG (Gdansk). Parkinson’s digital biomarker / wearable: Adamant Health (Kuopio). Genetic neurology NGS diagnostics: CeGaT (Tübingen). The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.